Brigham and Women’s Hospital study found that SST-treated patients had significantly lower pain scores in the post-operative care unit compared with patients in the two intravenous opioid contr… Study is the first to report on the use of DSUVIA® in the rapidly growing field of rhinology where otolaryngologists are performing painful nasal and sinus procedures in the office which were historic… Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA Breakthrough designation in line with a s… In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior loan with Oxford Finance HAYWARD, Calif. ,…

• Barchart is committed to ensuring digital accessibility for individuals with disabilities.
• Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M in the third quarter, a 217% increase over prior year $…
• It attempts to reflect the cash profit generated by a company’s operations.
• It’s calculated by multiplying the current market price by the total number of shares outstanding.

MarketBeat has tracked 2 news articles for AcelRx Pharmaceuticals this week, compared to 1 article on an average week. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Realtime quote and/or trades are not sourced from all markets.

Analysts Offer Insights on Healthcare Companies: Acelrx (ACRX) and Oak Street Health (OSH)

Provide specific products and services to you, such as portfolio management or data aggregation. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CompareACRX’s historical performanceagainst its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.

Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company’s balance sheet. Market cap or market capitalization is the total market value of all of a company’s outstanding shares. Represents the company’s profit divided by the outstanding shares of its common stock. AcelRx Pharmaceuticals shares reverse split before market open on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022.

View the ACRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the AcelRx Pharmaceuticals Inc real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACRX quote. AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006.

We’d like to share more about how we work and what drives our day-to-day business. Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. 52 week low is the lowest price of a stock in the past 52 weeks, or one year.

AcelRx Pharmaceuticals cut to hold from buy at Jefferies

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes.

Investing.com – U.S. equities were lower at the close on Wedneshttps://1investing.in/, as losses in the Technology, Industrials and Oil & Gas sectors propelled shares lower. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. The price-earnings ratio is a company’s share price to the company’s Earnings per Share. The ratio is used for evaluating companies and to find out whether they are overvalued or undervalued. The price-to-book ratio is a company’s current market price to its Book Value. Traditionally, any value under 1.0 is considered a good P/B value, indicating a potentially undervalued stock.

Price and EPS Surprise Chart

Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of ACRX stock can currently be purchased for approximately $0.67. Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat’s FREE daily newsletter. In the past three months, AcelRx Pharmaceuticals insiders have not sold or bought any company stock.

• AcelRx Pharma reported Q1 EPS of ($0.06), in-line with the analyst estimate of ($0.06).
• To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
• Maintaining independence and editorial freedom is essential to our mission of empowering investor success.

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more. There may be delays, omissions, or inaccuracies in the Information. To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

NEW YORK — Shares of AcelRx Pharmaceuticals plummeted 39% in active, premarket trade Monday, after the drug company said the U.S. Food and Drug Administration surprisingly requested and additional study to … This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies. AcelRx Pharmaceuticals delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. AcelRx Pharmaceuticals delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022.

The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share . It can also be calculated by dividing the company’s Market Cap by the Net Profit. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.

The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade.

Value investors frequently look for companies that have low price/book ratios. AcelRx Pharmaceuticals Inc.’s ACRX increased public offering of 12.5 million common shares priced at $3.31 a piece, flat with Thursday’s close. The pharmaceutical company, which focuses on treatments for acute and breakthr…

About the Company

These returns cover a days sales outstanding from January 1, 1988 through April 3, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

Physicians across Europe will now have access to DZUVEO®, a novel sublingual approach to acute pain management in medically supervised settings HAYWARD, Calif. , Oct. 27, 2022 /PRNewswire/ — AcelRx P… The study of 324 complex plastic surgery procedures demonstrated many benefits of using DSUVIA for analgesia, including avoiding the need for general anesthesia HAYWARD, Calif. , Oct. 31, 2022 /PRNews… Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M in the third quarter, a 217% increase over prior year $…

Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. AcelRx Pharmaceuticals Inc share price live 0.6614, this page displays NASDAQ ACRX stock exchange data.

BOSTON — Shares of AcelRx Pharmaceuticals rallied nearly 30% to $3.47 on Tuesday on news that it has made progress complying with certain U.S. regulatory requests related to the initiation of Phase III clin… By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. 10 people have searched for ACRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. AcelRx Pharmaceuticals has received a 53.29% net impact score from Upright.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock.

It’s calculated by averaging the closing stock price over the previous 50 trading days. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals.

Access advanced stock screeners, portfolio monitoring tools, proprietary research reports, and more. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction. AcelRx Pharma reported Q1 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $442 thousand versus the consensus estimate of $550… Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Oil & Gas, Technology and Consumer Goods sectors propelled shares higher.